Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOENIX-CCA4 futibatinib dose study in advanced cholangiocarcinoma with FGFR2 alterations
2023-503665-39-00Phase 2Authorised
- Sponsor
- Taiho Oncology
- Start
- Oct 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of futibatinib in cholangiocarcinoma (CCA) (2 arms), sponsored by Taiho Oncology. Primary endpoint: Objective response rate by independent central review. Planned start Oct 2023; status: authorised.
02
Drugs
futibatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2023-503665-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503665-39-00.